Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis
NCT02126098 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2014-04-29
Summary
The purpose of this study is to observe the clinical manifestation, Lab findings including chest CT scans, pathological findings and outcomes in chinese patients with pulminary vasculitis.
Conditions
- ANCA-associated Vasculitis
- Granulomatosis With Polyangiitis
- Microscopic Polyangiitis
- EosinphilicGranulomatosis With Polyangiitis
Sponsors & Collaborators
-
Peking Union Medical College Hospital
lead OTHER
Principal Investigators
-
Juhong Shi, M.D · Peking Union Medical College Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-05-31
- Primary Completion
- 2017-11-30
- Completion
- 2017-12-31
Countries
- China
Study Locations
More Related Trials
-
Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome
NCT05845723 ·Status: RECRUITING ·Phase: PHASE2
-
Phenotypic Expressions in a French Pseudoxanthoma-Elasticum Cohort
NCT01446380 ·Status: UNKNOWN
-
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)
NCT01862068 ·Status: COMPLETED
-
Pediatric Vasculitis Initiative
NCT02006134 ·Status: RECRUITING
-
Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome
NCT06660329 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Effect of Tofacitinib in Treating ANCA-associated Vasculitis
NCT04973033 ·Status: COMPLETED ·Phase: NA
-
Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.
NCT03290456 ·Status: RECRUITING ·Phase: NA
-
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
NCT05168475 ·Status: TERMINATED ·Phase: PHASE2
-
Establishment of an Early Warning Screening System for Hemophagocytic Lymphohistiocytosis a Multi-center, Prospective Study
NCT06614998 ·Status: RECRUITING
-
MMF Versus CTX in the Induction Treatment of ANCA Associated Vasculitis
NCT00301652 ·Status: COMPLETED ·Phase: NA
-
Inhalation of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Autoimmune Pulmonary Alveolar Proteinosis (PAP)
NCT02243228 ·Status: UNKNOWN ·Phase: PHASE2
-
Prospective Longitudinal Cohort Study of Vasculitis Patients
NCT04413331 ·Status: RECRUITING
-
Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis
NCT00001541 ·Status: COMPLETED
-
Alemtuzumab for ANCA Associated Refractory Vasculitis
NCT01405807 ·Status: UNKNOWN ·Phase: PHASE4
-
Defining Immune Tolerance in ANCA-associated Vasculitis (AAV)
NCT01934504 ·Status: TERMINATED
-
To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class III-IV LN
NCT00302549 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Antigen-specific T Cells in Patients With Antisynthetase Syndrome and Interstitial Lung Disease
NCT05984394 ·Status: RECRUITING
-
One-Time DNA Study for Vasculitis
NCT01241305 ·Status: RECRUITING
-
Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis
NCT05749666 ·Status: UNKNOWN ·Phase: PHASE3
-
The Longitudinal Evaluation of Autoimmune Pulmonary Alveolar Proteinosis
NCT03531996 ·Status: COMPLETED
-
Journey of Patients With Vasculitis From First Symptom to Diagnosis
NCT03410290 ·Status: COMPLETED
-
Pioglitazone Therapy for Chronic Granulomatous Disease
NCT03080480 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Rituximab and Belimumab Combination Therapy in PR3 Vasculitis
NCT03967925 ·Status: UNKNOWN ·Phase: PHASE2
-
Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis
NCT03316651 ·Status: UNKNOWN ·Phase: PHASE2
-
CellCept in p-ANCA Vasculitis
NCT00405860 ·Status: COMPLETED ·Phase: PHASE1